- Recruiting
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Updated: May 25, 2022
Anti-BCMA/Anti-CD3 Bispecific Antibody EMB-06
NCT04735575: Phase 1/2: Study of EMB-06 in Participants With Relapsed or Refractory Myeloma

A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.
Sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd
Locations
Australia
China
ClinicalTrials.gov Identifier: NCT04735575